Potential uses of omberacetam (Noopept©) in the early prevention and management of cognitive impairment

BACKGROUND. Cognitive impairment represents a growing global health challenge due to population aging and the increasing prevalence of chronic non-communicable diseases. Early stages of cognitive decline, including subjective cognitive decline and mild cognitive impairment, are considered the most promising therapeutic window for preventive intervention.

OBJECTIVE. To summarize expert opinions regarding the potential role of omberacetam (Noopept®) in early prevention and management of cognitive impairment.

MATERIALS AND METHODS. The article presents the resolution of an expert council meeting involving specialists in geriatrics, neurology, psychiatry, and internal medicine. Current evidence from experimental and clinical studies on the mechanisms of action and clinical efficacy of omberacetam was analyzed.

RESULTS. Omberacetam demonstrates multimodal neuroprotective effects, including stimulation of neurotrophic factors (BDNF and NGF), antioxidant activity, modulation of glutamatergic neurotransmission, and improvement of neuronal plasticity. Clinical studies have shown improvements in memory, attention, executive functions, and quality of life in patients with mild and moderate cognitive impairment of vascular, traumatic, and other origins. CONCLUSION. According to expert consensus, omberacetam may be considered as part of a complex therapeutic strategy for patients with early cognitive impairment, vascular risk factors, asthenic conditions, and organic CNS disorders. Further multicenter randomized clinical studies are required to strengthen the evidence base and evaluate the potential inclusion of omberacetam in clinical recommendations for the prevention and management of cognitive impairment.

1. Livingston G., Huntley J., Sommerlad A., et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Commission. Lancet. 2024 ; 403 (10431) : 1139–1204. DOI: 10.1016/S0140-6736(24)01296-0.

2. Petersen R. C., Lopez O., Armstrong M. J., et al. Practice guideline update summary: Mild cognitive impairment. Neurology. 2018 ; 90 (3) : 126–135. DOI: 10.1212/WNL.0000000000004826.

3. Safarova T. P., Kolykhanov I. V. Cognitive vulnerability in elderly patients with depression: who is at risk? Modern Therapy of Mental Disorders. 2025 ; 4 : 2–8 (In Russ.]. DOI: 10.48612/psyph/txgg-u7bv-mb26.

4. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014 ; 10 (6) : 844–852. DOI: 10.1016/j.jalz.2014.01.001.

5. O’Brien J. T., Thomas A. Vascular dementia. Lancet. 2015 ; 386 (10004) : 1698–1706. DOI: 10.1016/S0140-6736(15)00463-8.

6. [Mosolov S. N. Fundamentals of Psychopharmacotherapy. Moscow: Vostok; 1996 (In Russ.)].

7. Gudasheva T. A, Boyko S. S, Akparov V. Kh., et al.(1996), Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Letters. 1996 ; 391 (1–2) : 149–152. DOI: 10.1016/0014-5793(96)00722-3.

8. Seredenin S. B. Peptide neuroprotectors: experimental and clinical aspects. Experimental and Clinical Pharmacology. 2000 ; 63 (5) : 3–9 (In Russ.)].

9. Seredenin S. B., Voronina T. A., Ostrovskaya R. U. Neuroprotective properties of peptide nootropics. I. P. Pavlov Journal of Higher Nervous Activity. 2005 ; 55 (3) : 356–364 (In Russ.)].

10. Ostrovskaya R. U., Vakhitova Y. V., Kuzmina U. Sh., et al. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci. 2014 ; 21 (1) : 74. DOI: 10.1186/s12929-014-0074-2.

11. Ostrovskaya R. U., Gudasheva T. A. Dipeptide drug Noopept: design, pharmacological properties and mechanisms of action. Experimental and Clinical Pharmacology. 2021 ; 84 (2) : 41–52 (In Russ.)]. DOI: 10.30906/0869-2092-2021-84-2-41-52.

12. Neznamov G. G., Teleshova E. S. Comparative study of Noopept and piracetam in patients with mild cognitive impairment caused by organic brain diseases of vascular and traumatic origin. S. S. Korsakov Journal of Neurology and Psychiatry. 2008 ; 108 (3) : 33–42. (In Russ.)]. DOI: 10.1007/s11055-009-9128-4.

13. Shmyrev V. I., Kryzhanovsky S. M. Effectiveness of Noopept in the treatment of moderate cognitive impairment in patients with dyscirculatory encephalopathy. Consilium Medicum. 2009 ; 11 (9) : 37–41. (In Russ.)].

14. Yakhno N. N., Damulin I. V., Antonenko L. M. Noopept in the treatment of cerebrovascular insufficiency with moderate cognitive impairment. Attending physician. 2009. (5). (In Russ.)].

15. Barantsevich E. R., Posokhina O. V., Sturova Yu. V. Effectiveness of Noopept in dyscirculatory encephalopathy. S. S. Korsakov Journal of Neurology and Psychiatry. 2009 ; 109 (5) : 62–64. (In Russ.)].

16. Amelin A. V., Iliukhina A. Iu., Shmonin AA. Noopept in the treatment of mild cognitive impairment in patients with stroke. S. S. Korsakov Journal of Neurology and Psychiatry. 2011 ; 111 (10) : 44–46. (In Russ.)].

17. Gavrilova S. I., Kolyhalov I. V., Fedorova Ya. B. i dr. Opyt klinicheskogo primeneniya Noopepta v lechenii sindroma myagkogo kognitivnogo snizheniya. Sovremennaya terapiya psihicheskih rasstrojstv. 2008 ; (1) : 27–32. (In Russ.)].

18. Dolgova I. N., Starodubtseva A. I. Vascular cognitive impairment in young patients. S. S. Korsakov Journal of Neurology and Psychiatry. 2010 ; 110 (10) : 14–16 (In Russ.)].

19. Odinak M. M., Vorobyev S. V., Lobzin V. Yu., et al. Use of Noopept in patients with mild cognitive impairment of post-traumatic origin. Outpatient Physician Handbook. 2011 ; (2) : 56–59. (In Russ.)].

20. Levin O. S., Yunishchenko N. A., et al. Effectiveness of Noopept in patients with dyscirculatory hypertensive encephalopathy. Elderly Patient. 2016 ; 1 (5). (In Russ.)].

21. Dolgova I., Starodubtsev A. Correction of cerebrovascular disorders in patients with idiopathic arterial hypotension. Doctor = Vrach. 2013 ; 24 (12) : 27–31. (In Russ.)].

22. Dadasheva M. N., Gorenkov R. V., Kruglov V. A., et al. Possibilities nootropic drugs in non-demented patients with vascular cognitive disorders. Neurology, Neuropsychiatry, Psychosomatics. 2022 ; 14 (2) : 49–55. (In Russ.)]. DOI: 10.14412/2074-2711-2022-2-49-55.

23. Shishkova V. N., Kapustina L. A., Shishkov V. A., Vinokurov V. G. Assessment of Noopept Treatment Efficacy in Patients with Cognitive Impairments Associated with Cardiovascular Diseases. Nervous Diseases. 2024; (4) : 70–76. (In Russ.)]. DOI: 10.24412/2226-0757-2024-13193.

24. Koberskaya N. N., Ostroumova T. M. Near-moderate cognitive decline. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020 ; 12 (2) : 92–97. (In Russ.)]. DOI: 10.14412/2074-2711-2020-2-92-97.

25. Drapkina O. M., Berns S. A., Nikulina S. Yu., Solovieva E. Yu. Screening algorithm for predementia cognitive impairment in cardiovascular patients at a general practitioner's appointment. Expert Consensus Statement. Cardiovascular Therapy and Prevention. 2024 ; 23 (10 ): 4132. (In Russ.)]. DOI: 10.15829/1728-8800-2024-4132.